Summary
Poliomyelitis paralyzed and killed tens of thousands of Americans in the first half of the twentieth century, reaching its worst year in 1952 with over 57,000 cases. The disease struck with a cruel paradox: improvements in sanitation and hygiene made epidemics worse, not better, by delaying children’s first exposure to the virus past the age when maternal antibodies offered protection. The race to develop a vaccine consumed billions in charitable donations, split the scientific community between killed-virus and live-virus camps, and produced both Jonas Salk’s injectable vaccine in 1955 and Albert Sabin’s oral vaccine in 1961. The polio story reshaped American public health, pioneered the modern disease-charity model, and raised questions about human experimentation, scientific celebrity, and the ethics of medical research that remain unresolved.
The Paradox of Sanitation
Polio’s epidemiological history inverts the usual story about disease and progress. For most of human history, poliovirus circulated so widely that virtually all children encountered it in infancy, when maternal antibodies still provided some protection. Most infections produced no symptoms or only mild illness; the virus passed through and left lasting immunity. As cities cleaned their water supplies and improved sewage systems in the late nineteenth and early twentieth centuries, this early universal exposure ended. Children now met poliovirus for the first time at ages when paralysis was far more likely.(Oshinsky, 2005)
The disease that had been endemic and largely invisible became epidemic and terrifying. Oshinsky describes this as “the irony was unmistakable: the better the sanitation, the worse the epidemic.”(Oshinsky, 2005) The first recognized epidemic in the United States struck Vermont in 1894, when Dr. Charles Caverly recorded 132 cases of a “paralytic disease” affecting both adults and children.(Oshinsky, 2005) Within two decades, polio had become America’s most feared disease.
The human cost was immediate. In 1949, San Angelo, Texas, a city of 57,000, recorded the highest per-capita polio rate in American history.(Oshinsky, 2005) There were no drugs to treat the disease, no vaccine to prevent it, and no way to predict who would be struck next; as Oshinsky writes, the disease attacked rich and poor alike and seemed especially drawn to children.(Oshinsky, 2005)
From within vitalist medicine, Henry Lindlahr offered a causation theory that attributed poliomyelitis directly to smallpox vaccination. Writing in 1918, he reported treating “a number of cases of infantile paralysis that developed immediately after vaccination,” including a five-year-old boy whose paralysis had followed vaccination by two years; under natural treatment, Lindlahr claimed, the boy made a complete recovery.(Lindlahr, Henry, 1918) This argument was made before the poliovirus had been identified as a neurotropic enterovirus and before its fecal-oral transmission route was understood. The vaccine Lindlahr was criticizing was smallpox vaccine, not polio vaccine (which did not exist until 1955), and his causal account rested on temporal proximity rather than mechanism.
Early Research and the Rockefeller Institute
The Rockefeller Institute, founded in 1901, became the center of American polio research under the direction of virologist Simon Flexner.(Oshinsky, 2005) Flexner’s influence shaped the field for decades, but not always productively. His theory that poliovirus entered the body through the nose proved wrong, yet dominated American research for years and led to misguided interventions including zinc sulfate nasal sprays that damaged the nasal passages of thousands of children without preventing a single case of polio.(Oshinsky, 2005)
The catastrophic 1916 New York City epidemic killed over 2,000 people and paralyzed thousands more, triggering public panic on a scale not seen since the cholera epidemics of the nineteenth century.(Oshinsky, 2005) The epidemic also exposed the intersection of disease and prejudice: public health officials targeted immigrant neighborhoods in Brooklyn and the Lower East Side with quarantine measures, while affluent suburbs faced lighter enforcement.(Oshinsky, 2005) Despite decades of work at the Rockefeller Institute, by the 1930s there was still no vaccine, no cure, and no clear understanding of how the virus spread.(Oshinsky, 2005)
Roosevelt and the Transformation of Disease Philanthropy
Franklin D. Roosevelt contracted polio in August 1921 at age thirty-nine.(Oshinsky, 2005) His initial treatment under Dr. William Keen was later judged incorrect: the prevailing understanding of polio care was so limited that even eminent physicians could do little more than prescribe rest and hope.(Oshinsky, 2005) Roosevelt deliberately concealed the severity of his paralysis from the public, constructing what Oshinsky calls “a deception of epic proportions” sustained by a cooperative press corps that never photographed him in his wheelchair.(Oshinsky, 2005)
Roosevelt discovered Warm Springs, Georgia in 1924, turning a failing resort into the nation’s first dedicated polio rehabilitation center.(Oshinsky, 2005) His experience with polio, Oshinsky argues, became a political asset rather than a liability: it gave him an aura of courage and empathy that resonated with Depression-era voters.(Oshinsky, 2005)
The fundraising apparatus Roosevelt built around polio reshaped American health philanthropy. The Birthday Balls campaign, launched in 1934, raised funds through galas held on Roosevelt’s birthday across the country.(Oshinsky, 2005) In 1938, actor Eddie Cantor coined the name “March of Dimes,” urging radio listeners to send dimes directly to the White House; within days, 2,680,000 dimes arrived.(Oshinsky, 2005) The National Foundation for Infantile Paralysis, incorporated in 1938 under the leadership of Basil O’Connor, became the largest private funder of medical research in the world.(Oshinsky, 2005)
Roosevelt deliberately blurred the distinction between his personal story and the national cause, making polio’s conquest an extension of his political mission.(Oshinsky, 2005) The NFIP pioneered techniques of emotional fundraising, using images of disabled children, celebrity endorsements, and grassroots volunteer networks, that would become the template for every disease charity that followed.(Oshinsky, 2005)(Oshinsky, 2005)
The scale of that volunteer network was extraordinary. Beginning in 1950, the Mothers’ March sent local women door-to-door on designated evenings to collect coins from households that left their porch lights on as a signal of participation; by 1954, seven million volunteers had marched for the March of Dimes.(Oshinsky, 2005) By that year, the NFIP accounted for nearly half of all major health charity revenues, prompting critics to ask why a disease striking 50,000 Americans annually was receiving more money than conditions that killed millions.(Oshinsky, 2005)
The Park-Brodie Disaster and Institutional Caution
The philanthropic success did not translate immediately into research progress. In 1935, Maurice Brodie and William Park announced an experimental killed-virus polio vaccine that they intended to test in children. Several children who received the vaccine were paralyzed; at least one died. The disaster haunted the field for a generation and convinced many researchers that a safe polio vaccine was decades away.(Oshinsky, 2005) In response, Tom Rivers, the dean of American virology and chair of the NFIP’s Immunization Committee, drew up strict protocols requiring extensive animal testing, small-scale human trials, and careful stepwise progression before any vaccine could reach large numbers of people.(Oshinsky, 2005) These protocols would later become the object of contention when the Salk campaign gained momentum.
The Iron Lung and the Problem of Treatment
The iron lung (Drinker respirator), developed at Harvard in 1928, became the defining symbol of polio’s threat.(Oshinsky, 2005) Historian David Rothman argues that the iron lung established an ethical framework later applied to end-of-life care: who decides when to turn off the machine?(Oshinsky, 2005)
The NFIP’s response to epidemics extended beyond research funding to direct community intervention. In 1944, a devastating epidemic struck Hickory, North Carolina. With no proper facilities available, the community converted a dance hall into a fully equipped polio hospital in fifty-four hours, a feat the NFIP celebrated nationally as proof that community organization could substitute for institutional infrastructure.(Oshinsky, 2005)
Sister Elizabeth Kenny, an Australian nurse, introduced physiotherapy as an alternative to the standard treatment of rigid splinting and immobilization. Her approach, applying hot packs and encouraging movement, was resisted by the American medical establishment for years before being adopted as the standard of care.(Oshinsky, 2005) The institutional resistance to Kenny’s methods illustrates how professional hierarchies can delay the adoption of effective treatments when they originate outside the recognized credentialing system.(Oshinsky, 2005)
The NFIP’s reach extended to Black Americans, though always within the constraints of Jim Crow. Roosevelt spoke at the dedication of an infantile paralysis treatment unit at Tuskegee Institute in January 1941, which the NFIP helped fund as the only polio center in the Deep South serving Black patients. It was a segregated facility, an accommodation to the racial politics of the era that the foundation felt it could not avoid.(Oshinsky, 2005)
The Race for a Vaccine
Three researchers dominated the vaccine race: Jonas Salk at the University of Pittsburgh, Albert Sabin at the University of Cincinnati, and Hilary Koprowski at Lederle Laboratories.(Oshinsky, 2005) Their scientific disagreements became personal rivalries that shaped the politics of polio research for a generation.
The critical breakthrough came from outside the vaccine race entirely. In 1949, John Enders, Thomas Weller, and Frederick Robbins at Boston Children’s Hospital demonstrated that poliovirus could be grown in non-nervous tissue culture, work that won the 1954 Nobel Prize and made vaccine development practically possible for the first time.(Oshinsky, 2005) That same year, the NFIP funded a systematic typing program to classify all three strains of poliovirus (Type I, II, and III), spending $1.37 million and deploying 17,500 monkeys across four laboratories. Salk used his assignment to that program as a vehicle for developing his vaccine approach.(Oshinsky, 2005)
Koprowski’s Unauthorized Tests
Before Salk or Sabin had conducted any human trials, Hilary Koprowski at Lederle Laboratories quietly ran ahead. In the winter of 1948, he swallowed a mixture of attenuated Type II poliovirus himself, followed days later by his laboratory assistant. Both developed antibodies without becoming ill. Emboldened, Koprowski arranged to test the vaccine on seventeen residents of a New York State institution for the developmentally disabled, without obtaining parental consent or informing any oversight committee.(Oshinsky, 2005) At the 1951 NFIP immunization roundtable, Albert Sabin publicly condemned this testing as unethical. “How dare you,” he reportedly said. The room was shocked. Yet, as Oshinsky observes, Sabin was not opposed to human testing in principle; he was opposed to Koprowski doing it first.(Oshinsky, 2005)
Salk’s Background and Approach
Salk, the son of Jewish immigrants in the East Bronx, built his scientific approach under his mentor Thomas Francis Jr., who had pioneered the killed-virus influenza vaccine at the University of Michigan.(Oshinsky, 2005)(Oshinsky, 2005) Anti-Semitism shaped his career: despite strong credentials, he was denied positions at institutions that maintained quotas on Jewish faculty.(Oshinsky, 2005)
Sabin’s temperament was Salk’s opposite, fiercely competitive, intellectually arrogant, and certain that only a live-virus vaccine could produce lasting immunity.(Oshinsky, 2005) The scientific consensus favored Sabin’s position. Most virologists believed that a killed-virus vaccine could not generate durable immunity; the prevailing view held that only infection with a weakened but living virus could train the immune system properly.(Oshinsky, 2005)
Salk’s innovation was to combine the Enders tissue culture technique with a systematic killed-virus approach, inactivating poliovirus with formaldehyde while preserving its ability to stimulate antibodies.(Oshinsky, 2005) He controversially chose the Mahoney strain for Type I poliovirus, the most virulent available, reasoning that the strongest immune response would come from the most potent antigen.(Oshinsky, 2005)
Dorothy Horstmann’s 1952 discovery of polioviremia, that poliovirus traveled through the bloodstream before reaching the nervous system, provided the theoretical foundation for Salk’s approach. If the virus had a bloodstream phase, then circulating antibodies produced by a killed-virus vaccine could intercept it before it caused paralysis.(Oshinsky, 2005)
Human Experimentation and the Ethics of Urgency
Salk’s first human trial in 1952 used institutionalized residents of the D.T. Watson Home for Crippled Children, children who had already survived polio.(Oshinsky, 2005) The use of institutionalized children as research subjects illustrates the ethical norms of mid-century medical research, which permitted practices that later generations would judge unacceptable.(Oshinsky, 2005) Salk also vaccinated his own wife and three sons, a gesture of confidence that became part of his public mythology.(Oshinsky, 2005)
The early results from the Polk School trials were striking: every child developed measurable antibodies against all three poliovirus types, with levels in many cases matching those from natural infection. This was precisely what Salk had predicted, and precisely what Sabin had insisted was impossible.(Oshinsky, 2005)
The NFIP’s Internal Campaign
Harry Weaver, the NFIP’s director of research, was the internal champion who read Salk’s early work with a scientist’s eye and drove the push toward field trials. He had pushed the Immunization Committee to give Salk the resources he needed and championed a large-scale field trial over the committee’s own objections.(Oshinsky, 2005)
The committee, dominated by live-virus advocates including Sabin, Enders, and Howe, proved consistently obstructive. At the Hershey meeting in January 1953, Salk presented his Watson Home and Polk School results. The committee was unmoved: Sabin called the data preliminary, Enders demanded more animal testing, and Howe said the sample was too small. The committee refused to endorse a field trial.(Oshinsky, 2005) O’Connor responded by forming a separate Vaccine Advisory Committee that excluded the foundation’s existing grantees, specifically to prevent obstruction.(Oshinsky, 2005)
The NFIP backed Salk materially as well as institutionally. In January 1953 alone, the foundation gave him its largest annual grant to that point: $255,472, supporting a Pittsburgh laboratory that now included two assistant research professors, eleven research assistants, seven technicians, and a monkey colony of 500.(Oshinsky, 2005) The relationship had become historically novel: no scientist and no philanthropy had ever been bound together quite this way, with the foundation financing Salk’s laboratory, managing his celebrity, and staking its institutional existence on the outcome of his research.(Oshinsky, 2005)
Media Strategy and the Celebrity Scientist
The NFIP’s media strategy transformed Salk into a celebrity-scientist, a category that barely existed before polio. His March 1953 CBS radio broadcast introduced the vaccine to the American public before his results were fully published, a deliberate strategy by O’Connor to build public pressure for a field trial.(Oshinsky, 2005)(Oshinsky, 2005)
In February 1953, O’Connor invited an elite group of journalists, health officials, and researchers to the Waldorf-Astoria to hear Salk present his progress. Sabin, Enders, and Paul were not invited; there would be no dissenting voices in the room.(Oshinsky, 2005) Tom Rivers, who personally favored the live-virus approach, nonetheless endorsed Salk at the meeting, arguing that an effective stopgap was better than waiting years for a theoretically superior alternative.(Oshinsky, 2005) Sabin, meanwhile, wrote Salk privately urging him not to be pushed into premature field trials by Weaver, signing the letter with “affectionate regards”, advice that was simultaneously genuine scientific caution and self-interested competition.(Oshinsky, 2005)
After Harry Weaver made a coded public announcement that a promising vaccine was near, reporter John Troan of the Pittsburgh Press became the first to name Salk publicly as the researcher responsible. Within weeks, Salk’s photograph appeared in Time magazine under the caption “Ready for the big attack.”(Oshinsky, 2005)
The Pressure of Epidemic
The 1952 epidemic, the worst in American history, with 57,628 cases, 21,000 paralytic cases, and 3,145 deaths, intensified the pressure to move from laboratory to field trial.(Oshinsky, 2005)(Oshinsky, 2005) O’Connor suffered a heart attack in June 1952 at the height of the epidemic season and ignored his doctors’ orders to rest; as he reportedly said, “this is not a good time to be sick.”(Oshinsky, 2005)
The NFIP’s fundraising machinery was structurally dependent on an image of forward momentum. As one scientist observed, the foundation “could not afford to be unpopular” and “could not appear sluggish or over-cautious”, it was “trapped within its own image of dynamic optimism.”(Oshinsky, 2005) O’Connor’s NFIP had become so financially dominant that it could bypass its own scientific advisory committee when that committee urged caution.(Oshinsky, 2005) The boundary between scientific caution and institutional self-interest was, as Oshinsky shows, always ambiguous.(Oshinsky, 2005)
Designing the Field Trials
The design of the 1954 trials was itself contested. Salk objected strenuously to using a placebo on ethical grounds, arguing that giving children an inert injection while withholding a potentially life-saving vaccine was morally equivalent to causing paralysis: “every child who gets a placebo and becomes paralyzed will do so at my hands,” he wrote. Thomas Francis, once appointed to direct the independent evaluation, overrode this objection in favor of scientific rigor.(Oshinsky, 2005)
Julius Youngner, Salk’s top laboratory assistant, harbored a different grievance. He accused Salk of claiming first authorship on a paper Youngner had written by claiming to have “lost” the original manuscript and “reconstructing” it with his own name listed first. When Youngner questioned the change, Salk said that since he had reconstructed the paper it was only fair his name appear first. Youngner concluded this broke their relationship but did not pursue the argument further.(Oshinsky, 2005)
Thomas Francis Jr. agreed to direct the independent Vaccine Evaluation Center at the University of Michigan only after negotiating complete independence from the NFIP: control over data release, trial design, and his own research funding regardless of outcome. The desperate foundation accepted every condition.(Oshinsky, 2005) The trials were designed as two simultaneous experiments: a double-blind placebo-controlled injected trial in 84 counties and an observed-control trial in 127 counties, spanning 211 counties in 44 states with 1.5 million children.(Oshinsky, 2005)
One technical decision reduced the vaccine’s effectiveness before a single shot was given. The NIH required Salk to use Merthiolate as a preservative over his objections. The preservative reduced the potency of the killed Type I virus; Salk later recalled bitterly that “the field trial would have been close to 100 percent effective if the Merthiolate hadn’t been rammed down my throat.”(Oshinsky, 2005)
The Field Trials of 1954
The 1954 Salk vaccine field trials were the largest controlled public health experiment in American history, enrolling nearly 1.8 million children.(Oshinsky, 2005) The operational scale was staggering: 14,000 school principals, 50,000 teachers, 220,000 volunteer workers, and 20,000 physicians and public health officers coordinated the trial across hundreds of counties.(Oshinsky, 2005) O’Connor gambled $9 million on stockpiling nine million doses before the results were known.(Oshinsky, 2005)
The trials nearly collapsed before they completed enrollment. On April 4, 1954, radio broadcaster Walter Winchell went on air with a “special bulletin” warning that the Salk vaccine “may be a killer,” citing anonymous tips. Estimates placed the number of children withdrawn from participation at roughly 150,000 in the days that followed.(Oshinsky, 2005)
On April 12, 1955, Thomas Francis Jr. announced at the University of Michigan that the Salk vaccine was 60-90 percent effective against paralytic polio.(Oshinsky, 2005) Church bells rang. Factory whistles blew. Salk became the most celebrated scientist in America overnight.
Salk’s own conduct at the Ann Arbor ceremony introduced a sour note. Speaking after Francis’s announcement, he informed the audience that his improved 1955 formulation was already superior to the one just tested. Francis, who had spent two years on the evaluation, was furious: Salk had made it seem as though the vaccine just declared safe and effective was already obsolete.(Oshinsky, 2005)
The Cutter Incident
The triumph lasted thirteen days. On April 24, 1955, Susan Pierce of Pocatello, Idaho became paralyzed, the first confirmed case of vaccine-associated polio traced to Cutter Laboratories of Berkeley, California.(Oshinsky, 2005) The Cutter incident ultimately caused 79 cases of paralytic polio among vaccinated children, 105 among family contacts, and 20 in the wider community, with several deaths.(Oshinsky, 2005)
The technical cause was that virus particles clumped together during production, creating sediment that shielded live virus from the formaldehyde inactivation process.(Oshinsky, 2005) Julius Youngner had warned Salk before the vaccine’s release that the filtration protocols were inadequate, but Salk dismissed the concern.(Oshinsky, 2005) Surgeon General Leonard Scheele halted all Cutter vaccine distribution and temporarily suspended the entire national vaccination program.(Oshinsky, 2005)
The political fallout was severe. Secretary of Health Oveta Culp Hobby resigned in July 1955 partly as a consequence of the regulatory failure, while Congress responded to the crisis by dramatically expanding NIH funding, growing its budget from $81 million in 1955 to more than $400 million by the end of the decade.(Oshinsky, 2005)
The Cutter incident reshaped American vaccine regulation. Following revised manufacturing protocols, the NIH’s Laboratory of Biologics Control was given expanded authority, and federal oversight of vaccine production was permanently strengthened.(Oshinsky, 2005)
From Salk to Sabin
Salk vaccine annual case totals fell from 28,985 in 1955 to 5,485 in 1956 and to 2,499 in 1957.(Oshinsky, 2005) But Sabin’s oral vaccine, tested on ten million Soviet children with the cooperation of virologist Mikhail Chumakov, offered practical advantages: it required no injection, was cheaper, and generated intestinal immunity that could interrupt community transmission.(Oshinsky, 2005) Dorothy Horstmann of Yale, sent by the WHO to evaluate the Soviet trials, returned with a positive assessment that provided Western credibility for the results.(Oshinsky, 2005)
The Ethics of Sabin’s Own Trials
The path to Sabin’s oral vaccine involved its own ethical complications. Sabin conducted his initial human trials on thirty adult male prisoners at the federal reformatory in Chillicothe, Ohio, paying each $25. The irony was not lost on those who remembered his public condemnation of Koprowski’s unannounced human experiments in 1951: Sabin was not opposed to testing on institutionalized populations, only to someone else doing it first.(Oshinsky, 2005)
Koprowski, meanwhile, conducted a 1956 trial of his own oral vaccine on institutionalized children in Belfast. Several children showed signs of neurological damage after the virus appeared to revert to a more virulent form in the gut; one scientist described the episode as “going in like a lamb but coming out like a lion.” The Belfast disaster effectively eliminated Koprowski from the oral vaccine race, narrowing competition to Sabin.(Oshinsky, 2005)
Sabin’s key strategic move was to conduct his large-scale trials not in the United States but in the Soviet Union. No American regulatory body would have sanctioned trials on ten million subjects; Sabin exploited Cold War scientific relationships to accumulate the trial data he needed to displace Salk, using communist-bloc populations as his proving ground.(Oshinsky, 2005)
The Transition in American Practice
The American Medical Association endorsed Sabin’s oral vaccine before federal licensing in 1961.(Oshinsky, 2005) Community vaccination drives called “Sabin Sundays” administered the three vaccine types in sequence at schools, churches, and shopping centers; the spectacle of children swallowing their way to immunity on a sugar cube gave the oral vaccine an enormous popular advantage over the injectable approach.(Oshinsky, 2005) By 1963, the oral Sabin vaccine had largely replaced the injectable Salk vaccine in American public health practice.(Oshinsky, 2005)
The NFIP recognized that its organizational survival required adapting to a world where polio was no longer a mass annual crisis. An internal planning memo titled “Beyond Polio,” circulated in 1958, made the case for shifting the foundation’s mission toward birth defects and other childhood conditions. With polio cases falling, the March of Dimes needed a new disease to survive.(Oshinsky, 2005)
In 2000, the CDC reversed this policy and returned to the Salk injectable vaccine as the exclusive recommendation for American children, after the rare risk of vaccine-derived paralysis from the live oral vaccine became the primary safety concern in a near-elimination setting.(Oshinsky, 2005)
Aftermath: The Scientists and Their Legacies
Salk After the Vaccine
The replacement of the Salk vaccine by Sabin’s was a professional humiliation Salk never fully accepted.(Oshinsky, 2005) His conflicts with Chancellor Edward Litchfield over the funding and control of the proposed Salk Institute grew bitter, and he left Pittsburgh for good; he divorced his wife Donna in 1968 and in 1970 married French artist Françoise Gilot, former companion of Pablo Picasso.(Oshinsky, 2005) He channeled his ambitions into institution-building. The Salk Institute for Biological Studies opened in La Jolla, California in 1963, designed by architect Louis Kahn with twin concrete laboratory blocks flanking a travertine courtyard open to the Pacific. Salk called it his “temple of Zeus,” envisioning a place where scientists and humanists would work side by side.(Oshinsky, 2005)
In the 1980s, Salk turned his attention to AIDS, convinced that his killed-virus approach could produce a therapeutic vaccine. He co-founded the Immune Response Corporation to develop it. Before clinical trials began, he accepted stock in the company eventually valued at roughly $3 million, a conflict of interest that drew criticism from the scientific community.(Oshinsky, 2005)
The bitterness within his former team surfaced publicly in 1993. At a Pittsburgh ceremony marking the fortieth anniversary of the vaccine announcement, Julius Youngner stood and accused Salk directly of having claimed sole credit for a team effort, erasing the contributions of Youngner, Elsie Ward, and others from the historical record. Salk offered no real response.(Oshinsky, 2005)
Albert Sabin died on March 3, 1993, of heart failure. Jonas Salk died on June 23, 1995, also of heart failure. The two men had never reconciled. The rivalry that had defined their careers ended as it had lived, in silence and estrangement.(Oshinsky, 2005)
Post-Polio Syndrome and Survivors
For many of the approximately 400,000 surviving polio patients in the United States, the disease did not end with recovery. Post-polio syndrome, a late-onset condition of fatigue, new muscle weakness, and joint pain appearing decades after the original infection, was estimated by the 1980s and 1990s to affect between 25 and 50 percent of that population. For them, the war against polio had never ended.(Oshinsky, 2005)
Legacy
The WHO launched a global polio eradication initiative in 1987 when approximately 300,000 children were being paralyzed annually; by 2000, the number had dropped below 1,000.(Oshinsky, 2005) Rotary International committed $500 million and the Bill and Melinda Gates Foundation approximately $1 billion to the effort.(Oshinsky, 2005)
The eradication campaign was not without setbacks. In 2003-2004, Islamic leaders in Kano state, Nigeria claimed the oral polio vaccine was a Western plot to sterilize Muslim children or infect them with HIV. Vaccination efforts collapsed in the region, and polio spread from Kano to twelve countries that had previously eradicated the disease, a demonstration that even technically solved public health problems remain vulnerable to the politics of mistrust.(Oshinsky, 2005)
The victory over polio carried its own hidden costs. Simian virus 40 (SV40), a monkey virus known to cause cancer in laboratory animals, contaminated the early Salk vaccine produced between 1954 and 1963 because the vaccine was grown in rhesus monkey kidney cells harboring the latent virus. An estimated 98 million Americans received SV40-contaminated doses before the contamination was detected and the cell substrate changed.(Oshinsky, 2005) Subsequent epidemiological study of that cohort found no statistically significant increase in cancer rates, the contamination did not appear to cause the cancer it was capable of causing in laboratory settings, but the episode stands as an enduring emblem of the haste and regulatory inadequacy that characterized the era.(Oshinsky, 2005)
Oshinsky argues that polio is, above all else, an American story: no other country came close to matching the public hysteria and cultural impact it generated in the United States, nor the extraordinary national effort mounted to combat it.(Oshinsky, 2005) The story’s broader significance lies in what it reveals about American voluntarism, private philanthropy, and the complex relationship between scientific caution and public urgency.(Oshinsky, 2005) Lewis Thomas later testified that polio was among the major threats of the 1930s that had “literally vanished” by the late twentieth century.(Porter, 1997) But the triumph was neither clean nor inevitable: it was shadowed by ethical compromises in human experimentation, by regulatory failures that cost lives, and by personal rivalries that distorted the direction of research for a generation.
See Also
- vaccination
- public-health
- epidemic-disease
- epidemiology
- edward-jenner
- professionalization
- medical-ethics
Sources
[Auto-generated from evidence card IDs listed in frontmatter]